



## **Neurocrine Biosciences Announces Pricing Of Public Offering of 3,500,000 Shares of Common Stock**

December 3, 2001

SAN DIEGO, Dec. 3 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has priced a public offering of 3,500,000 shares of common stock at a price of \$46.75 per share. The company offered all of the 3,500,000 shares. The underwriters have a 30-day option to purchase up to 525,000 additional shares of common stock from the company solely to cover over-allotments, if any.

The joint bookrunning managers for the offering were Deutsche Banc Alex. Brown and Credit Suisse First Boston Corporation. Co-managers of this offering were CIBC World Markets Corp., Lehman Brothers Inc., and UBS Warburg LLC.

Copies of the final prospectus supplement may be obtained from the Prospectus Departments at Deutsche Banc Alex. Brown, One South Street, Baltimore, MD 21202, (410) 895-2070, Credit Suisse First Boston Corporation, Eleven Madison Avenue, New York, NY 10010, (212) 325-2000 or from the offices of any of the managing underwriters identified above.

This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. A registration statement relating to these securities has been filed with and has been declared effective by the Securities and Exchange Commission.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders.

MAKE YOUR OPINION COUNT - [Click Here](#)

<http://tbutton.prnewswire.com/prn/11690X40456576>

SOURCE Neurocrine Biosciences, Inc.

Web site: <http://www.neurocrine.com>

CONTACT: Elizabeth Foster or Paul Hawran, both of Neurocrine Biosciences, Inc., +1-858-658-7600